Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Will Resubmit COX-2 Inhibitor In The U.S. In 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Prexige is approved in EU and Canada for osteoarthritis symptoms, company announces.

You may also be interested in...



Prexige Review Will Not Include FDA Arthritis Drugs Advisory Committee

Novartis expects action later this year on lumiracoxib after resubmitting the application, the company tells “The Pink Sheet” DAILY.

Prexige Review Will Not Include FDA Arthritis Drugs Advisory Committee

Novartis expects action later this year on lumiracoxib after resubmitting the application, the company tells “The Pink Sheet” DAILY.

Novartis Bullish About Prexige; Anticipates Blockbuster Potential

Company takes a more bullish stance on its COX-2 inhibitor than Merck, which has assumed FDA approval of its Vioxx follow-on product Arcoxia in 2007.

Related Content

Topics

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel